Ethereum treasury company Propanc Biopharma reaches up to $100 million strategic financing agreement with Hexstone Capital
ChainCatcher reported that Propanc Biopharma, a biopharmaceutical company adopting an Ethereum treasury strategy, has announced a strategic financing agreement with family office Hexstone Capital for up to $100 million. Propanc CEO James Nathanielsz stated that this financing will accelerate the development of the company’s clinical pipeline, and they plan to grow the value of their digital asset treasury to $100 million or more within the next 12 months.
Hexstone Capital has previously invested in several companies with digital asset treasuries, involving BTC, ETH, SOL, DOGE, and other digital assets. According to previous reports, in early September Propanc Biopharma announced plans to acquire $100 million worth of Ethereum.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Sector Update: Tech Stocks Fall Monday Afternoon
First Solar Faces Pricing Pressure Amid High Inventory, Slow Project Starts, KeyBanc Says
Masonglory prices US$ 1 million private placement at US$ 1.50 per share
1.1 Million XRP Ledger Payments: What Pushes It So High?
Crypto prices
More
